|
|
|
LifeScienceHistory.com - Check us out on Instagram
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Neurotez, Inc.
| | | Phone: | (908) 988-1340 | Fax: | (908) 864-8957 | Year Established: | 2004 | Main Contact: | Nikolaos Tezapsidis, Ph.D., President, CEO & Chairman | | Other Contacts: | Michael J. Hoy, M.S., Director of Regulatory Affairs Eugene J. Oliva, MBA, Acting CFO Jane M. Johnston, PhD, Executive Direector, R&D
| | Company Description | Neurotez uses biochemistry, molecular & cell biology and in vivo models to identify potential biopharmaceuticals and has utilized a novel screening procedure for protein candidates amenable to therapeutic manipulation. The company's lead biopharmaceutical is Leptin, an adipocyte hormone thought to be controling energy homeostasis, as a replacement therapy in elderly and Alzheimer's disease (AD) patients (patent pending). The company has also identified a novel protein-protein interaction in a subset of familial cases of early onset AD. This abnormal interaction between mutated Presenilin with CLIP-170 is linked to higher Abeta levels, a small peptide believed to be the culprit of the disease pathology. | |
|
|
|
|
|